Cite
Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial
MLA
Stambler, Bruce S., et al. “Self-Administered Intranasal Etripamil Using a Symptom-Prompted, Repeat-Dose Regimen for Atrioventricular-Nodal-Dependent Supraventricular Tachycardia (RAPID): A Multicentre, Randomised Trial.” The Lancet, vol. 402, no. 10396, July 2023, pp. 118–28. EBSCOhost, https://doi.org/10.1016/S0140-6736(23)00776-6.
APA
Stambler, B. S., Camm, A. J., Alings, M., Dorian, P., Heidbuchel, H., Houtgraaf, J., Kowey, P. R., Merino, J. L., Mondésert, B., Piccini, J. P., Pokorney, S. D., Sager, P. T., Verma, A., Wharton, J. M., Bharucha, D. B., Plat, F., Shardonofsky, S., Chen, M., Ip, J. E., … Al-Zoebi, A. (2023). Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial. The Lancet, 402(10396), 118–128. https://doi.org/10.1016/S0140-6736(23)00776-6
Chicago
Stambler, Bruce S, A John Camm, Marco Alings, Paul Dorian, Hein Heidbuchel, Jaco Houtgraaf, Peter R Kowey, et al. 2023. “Self-Administered Intranasal Etripamil Using a Symptom-Prompted, Repeat-Dose Regimen for Atrioventricular-Nodal-Dependent Supraventricular Tachycardia (RAPID): A Multicentre, Randomised Trial.” The Lancet 402 (10396): 118–28. doi:10.1016/S0140-6736(23)00776-6.